These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 24596215

  • 1. PML nuclear bodies mediate the therapeutic response of APL cells.
    Cancer Discov; 2014 Mar; 4(3):OF20. PubMed ID: 24596215
    [Abstract] [Full Text] [Related]

  • 2. Curing APL through PML/RARA degradation by As2O3.
    Lallemand-Breitenbach V, Zhu J, Chen Z, de Thé H.
    Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
    [Abstract] [Full Text] [Related]

  • 3. Autophagic degradation of an oncoprotein.
    Bøe SO, Simonsen A.
    Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
    [Abstract] [Full Text] [Related]

  • 4. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R, de Thé H.
    Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
    [Abstract] [Full Text] [Related]

  • 5. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
    Zhu G.
    Curr Pharm Biotechnol; 2013 Jun; 14(9):849-58. PubMed ID: 24433507
    [Abstract] [Full Text] [Related]

  • 6. Function of PML-RARA in Acute Promyelocytic Leukemia.
    Testa U, Pelosi E.
    Adv Exp Med Biol; 2024 Jun; 1459():321-339. PubMed ID: 39017850
    [Abstract] [Full Text] [Related]

  • 7. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
    Vitoux D, Nasr R, de The H.
    Int J Biochem Cell Biol; 2007 Jun; 39(6):1063-70. PubMed ID: 17468032
    [Abstract] [Full Text] [Related]

  • 8. APL, a model disease for cancer therapies?
    de Thé H, Chelbi-Alix MK.
    Oncogene; 2001 Oct 29; 20(49):7136-9. PubMed ID: 11704841
    [No Abstract] [Full Text] [Related]

  • 9. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
    Ablain J, Rice K, Soilihi H, de Reynies A, Minucci S, de Thé H.
    Nat Med; 2014 Feb 29; 20(2):167-74. PubMed ID: 24412926
    [Abstract] [Full Text] [Related]

  • 10. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
    Lång E, Grudic A, Pankiv S, Bruserud O, Simonsen A, Bjerkvig R, Bjørås M, Bøe SO.
    Blood; 2012 Jul 26; 120(4):847-57. PubMed ID: 22692509
    [Abstract] [Full Text] [Related]

  • 11. The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies.
    de Thé H, Le Bras M, Lallemand-Breitenbach V.
    J Cell Biol; 2012 Jul 09; 198(1):11-21. PubMed ID: 22778276
    [Abstract] [Full Text] [Related]

  • 12. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
    Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi PP, Rochette-Egly C, Zhu J, de Thé H.
    Nat Med; 2008 Dec 09; 14(12):1333-42. PubMed ID: 19029980
    [Abstract] [Full Text] [Related]

  • 13. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
    Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de Thé H.
    Clin Cancer Res; 2009 Oct 15; 15(20):6321-6. PubMed ID: 19808868
    [Abstract] [Full Text] [Related]

  • 14. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
    Guo W, Wang H, Zhao W, Zhu J, Ju B, Wang X.
    Chin Med J (Engl); 2001 Jan 15; 114(1):30-4. PubMed ID: 11779431
    [Abstract] [Full Text] [Related]

  • 15. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
    Isakson P, Bjørås M, Bøe SO, Simonsen A.
    Blood; 2010 Sep 30; 116(13):2324-31. PubMed ID: 20574048
    [Abstract] [Full Text] [Related]

  • 16. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
    Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, Peres L, Berthier C, Soilihi H, Raught B, de Thé H.
    Cancer Cell; 2010 Jul 13; 18(1):88-98. PubMed ID: 20609355
    [Abstract] [Full Text] [Related]

  • 17. Curing APL: differentiation or destruction?
    Kogan SC.
    Cancer Cell; 2009 Jan 06; 15(1):7-8. PubMed ID: 19111876
    [Abstract] [Full Text] [Related]

  • 18. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
    Zhu J, Lallemand-Breitenbach V, de Thé H.
    Oncogene; 2001 Oct 29; 20(49):7257-65. PubMed ID: 11704854
    [Abstract] [Full Text] [Related]

  • 19. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D, Mistry AR, Solomon E, Guidez F.
    Cancer Treat Res; 2010 Oct 29; 145():219-35. PubMed ID: 20306254
    [Abstract] [Full Text] [Related]

  • 20. Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.
    de Thé H, Pandolfi PP, Chen Z.
    Cancer Cell; 2017 Nov 13; 32(5):552-560. PubMed ID: 29136503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.